Antifungal Resistance Evolution Serial Passage Study

Antifungal Resistance Risk Assessment for Early Discovery Programs

Early antifungal discovery teams often need to know whether a promising candidate can keep activity under repeated drug pressure, not only whether it inhibits a test strain once. Serial passage studies answer that practical question by watching susceptibility change over time while resistant subpopulations compete, adapt, or lose fitness across controlled experimental cycles.

For programs comparing new chemotypes, combination concepts, or mechanism-of-action hypotheses, resistance-evolution data can expose weak leads before expensive animal work and help prioritize compounds with more durable pharmacology. Creative Biolabs provides antifungal resistance evolution serial passage studies that connect MIC tracking, genomic analysis, and fitness profiling into one decision-ready service package for early preclinical teams seeking clearer compound risk stratification.

Core Study Questions

•Does repeated exposure drive a measurable MIC increase?
•Which mutations or genome changes appear during selection?
•Is resistance stable, reversible, or associated with a fitness cost?
•How should the candidate be ranked against backup compounds?

Serial Passage Study Design for Antifungal Resistance Evolution

We build study plans around the compound class, fungal species, baseline susceptibility, desired selection pressure, and downstream mechanism questions, then connect every experimental step to a clear preclinical decision.

What We Measure

MIC Shift Trajectory

Baseline and passage-by-passage MIC or MIC₅₀ readouts reveal whether susceptibility drift is gradual, stepwise, or absent under defined exposure conditions.

Mutation and Genome Mapping

Selected endpoint populations or representative clones can be profiled for SNVs, indels, copy-number changes, aneuploidy signals, or candidate resistance-gene changes.

Fitness and Stability

Drug-free back-passage, growth-curve comparison, and competitive fitness formats help determine whether acquired resistance carries a practical biological penalty.

Exposure Architecture

We configure fixed-concentration, stepwise-escalation, sub-MIC, or comparative drug-pressure designs to reflect the question your team needs answered. Passage interval, inoculum handling, replicate depth, and endpoint collection are predefined so the output can distinguish true adaptation from assay noise.

Pathogen Panel Selection

Study panels may include Candida, Aspergillus, dermatophyte, or project-specific fungal isolates. We align species, strain background, and starting susceptibility with your discovery hypothesis, including resistant comparators or clinically relevant reference strains when available.

Mechanism Linkage

Where a mechanism-of-action hypothesis exists, we map resistance-associated changes back to target genes, efflux pathways, stress-response networks, sterol biology, cell-wall pathways, or broader genome plasticity so resistance results become interpretable rather than descriptive.

Decision Framing

Final interpretation separates favorable profiles, manageable liabilities, and red-flag liabilities. Your team receives a clear narrative for lead ranking, backup-candidate selection, combination exploration, and follow-up susceptibility or virulence testing.

Antifungal Resistance Evolution Study Deliverables for Candidate Ranking

Deliverables are organized for discovery leaders who need to compare candidates quickly while keeping the underlying microbiology and genomics traceable.

Deliverable	Content Included	Discovery Value
Serial Passage Dataset	Passage scheme, fungal growth observations, dose condition records, susceptibility readouts, and replicate-level MIC or MIC₅₀ trends.	Shows whether resistance appears rapidly, slowly, or not within the study window.
Resistance-Mechanism Map	Candidate mutation list, affected pathways, population or clone-level genome findings, and interpretation against known or hypothesized antifungal targets.	Connects susceptibility shifts to plausible biological mechanisms.
Fitness-Cost Profile	Growth-curve, back-passage, recovery, or competitive-fitness outputs comparing evolved populations with parental controls.	Clarifies whether resistance is likely to persist without drug pressure.
Candidate Risk Summary	A concise technical report with figures, study limitations, recommended follow-up assays, and candidate-ranking implications.	Supports go/no-go review and next-study planning.

Resistance Evolution Study Workflow

The workflow is built to preserve experimental discipline while giving discovery teams interpretable checkpoints before committing to deeper profiling.

Typical Inputs

Candidate compound information, target species, available MIC data, preferred comparators, formulation or solvent constraints, and any existing mechanism, resistance-gene, or cytotoxicity observations.

1

Protocol Scoping

Define fungal panel, exposure mode, passage duration, sampling frequency, controls, and decision thresholds.

2

Baseline Susceptibility

Confirm starting MIC ranges and growth behavior so the passage plan begins from an interpretable baseline.

3

Serial Passage and Sampling

Apply repeated exposure, collect defined passage endpoints, and preserve populations or clones for downstream analysis.

4

MIC, Genome, and Fitness Readouts

Measure susceptibility shifts, map resistance-linked genetic changes, and assess growth or stability costs.

5

Integrated Risk Interpretation

Summarize resistance propensity, mechanism plausibility, study limitations, and recommended follow-up experiments.

Published Data Supporting Antifungal Resistance Evolution Studies

Recent research using Candida auris clinical isolates showed how short serial passage under fluconazole pressure can reveal rapid susceptibility shifts, genome copy-number changes, and point mutations within evolved populations. The study also compared drug-free, low-drug, and high-drug conditions, showing why selection intensity, isolate background, and replicate structure matter when interpreting whether a candidate creates a meaningful resistance liability. For discovery programs, this supports a study model that captures both obvious MIC escalation and quieter genome-level adaptation.

The image illustrates how MIC readouts and genome-level mapping can be paired after an in vitro evolution experiment to connect phenotype with mechanism, including changes that may otherwise remain hidden in endpoint susceptibility data alone. Creative Biolabs can provide related serial passage, susceptibility, genome-mapping, and fitness-cost studies to help antifungal teams evaluate resistance liability before advancing a lead candidate or selecting a backup series.

Fluconazole susceptibility and karyotype changes in evolved Candida auris populations. (OA Literature) — Fig.1 Determination of fluconazole MICs and genome karyotypes of *in vitro* evolution populations. ^1,2

Why Creative Biolabs for Antifungal Resistance Evolution Testing

01

Integrated Microbiology

Susceptibility testing, fungal growth handling, and resistance interpretation are planned together instead of treated as isolated assays.

02

Mechanism-Aware Design

Study endpoints can be aligned to target engagement, efflux, sterol pathway, cell-wall, stress-response, or virulence-related hypotheses.

03

Decision-Ready Reporting

Reports emphasize candidate ranking, resistance liability, and practical next steps, not just raw MIC tables.

04

Expandable Study Path

Serial passage results can flow into MoA testing, virulence-factor assays, combination screening, or additional safety-focused profiling.

Related Antifungal Discovery Services

Resistance-evolution studies become more powerful when paired with orthogonal susceptibility, mechanism, and virulence readouts. These related services can be combined into a staged antifungal profiling program.

Antifungal Susceptibility Test

Baseline and comparative activity profiling for lead optimization.

Antifungal MoA Study

Mechanism-focused assays that contextualize resistance pathways.

Fungal Virulence Factor Assay

Virulence-associated endpoints for expanded candidate characterization.

Frequently Asked Questions

It is most useful after a candidate has credible baseline activity but before the program commits heavily to animal studies, formulation investment, or full backup-series prioritization. Running the study early can reveal resistance liabilities while chemistry options are still flexible.

Yes. Comparative designs can evaluate several candidates, a reference antifungal, and selected concentrations across the same strain panel. This is especially helpful for ranking compounds with similar starting MIC values but potentially different resistance trajectories.

Study panels can be adapted for project-relevant fungi, including Candida species and other fungal pathogens where growth conditions, passage timing, and susceptibility methods can be controlled appropriately. The final panel is selected during scoping.

Not always. For a fast screen, MIC-shift and growth endpoints may be sufficient. Sequencing becomes more valuable when susceptibility changes are observed, when mechanism hypotheses need support, or when resistant clones must be compared against parental strains.

Yes. Depending on the project, fitness-cost profiling may include growth curves, drug-free back-passage, colony comparison, or competitive formats. These readouts help determine whether resistance is biologically costly or likely to remain stable.

Other Resources

Creative Biolabs' Live Biotherapeutics - Brochure

Probiotic Strain Products for NGP Research - Brochure

Custom Small-scale Probiotic Production

Live Biotherapeutics - Creative Biolabs - Video

References

Burrack, Laura S., et al. "Genomic diversity across Candida auris clinical isolates shapes rapid development of antifungal resistance in vitro and in vivo." mBio 13.4 (2022): e00842-22. https://doi.org/10.1128/mbio.00842-22
Distributed under Open Access license CC BY 4.0, without modification.